ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01687985
Recruitment Status : Completed
First Posted : September 19, 2012
Last Update Posted : July 16, 2014
Sponsor:
Information provided by (Responsible Party):
Braintree Laboratories

Brief Summary:
A pilot study to evaluate the safety and efficacy of multiple BLI801 doses in constipated adults.

Condition or disease Intervention/treatment Phase
Constipation Drug: BLI801 laxative - low dose Drug: BLI801 laxative - high dose Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults
Study Start Date : August 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Arm Intervention/treatment
Experimental: BLI801 laxative - low dose
BLI801 laxative - oral solution
Drug: BLI801 laxative - low dose
BLI801 laxative - oral solution

Experimental: BLI801 laxative - high dose
BLI801 laxative - oral solution
Drug: BLI801 laxative - high dose
BLI801 laxative - oral solution
Other Name: BLI801




Primary Outcome Measures :
  1. Treatment Success [ Time Frame: 4 weeks ]
    percent of patients experiencing a response in 3 out of 4 weeks of treatment


Secondary Outcome Measures :
  1. serum chemistry [ Time Frame: 4 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Male or female subjects at least 18 years of age

Constipated, defined by ROME definition:

Otherwise in good health, as determined by physical exam and medical history

Exclusion Criteria:

Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon

Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments

Subjects who are allergic to any BLI801 component

Subjects currently taking narcotic analgesics or other medications known to cause constipation

Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures

Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days

Subjects with an active history of drug or alcohol abuse


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01687985


Locations
United States, California
Anaheim Clinical Trials
Anaheim, California, United States, 92801
United States, Massachusetts
Commonwealth Clinical Studies
Brockton, Massachusetts, United States, 02302
United States, Tennessee
Clinsearch
Chattanooga, Tennessee, United States, 37421
Memphis Gastroenterology
Germantown, Tennessee, United States, 38138
Sponsors and Collaborators
Braintree Laboratories
Investigators
Study Director: John McGowan, MPH Braintree Laboratories, Inc.

Responsible Party: Braintree Laboratories
ClinicalTrials.gov Identifier: NCT01687985     History of Changes
Other Study ID Numbers: BLI801-202
First Posted: September 19, 2012    Key Record Dates
Last Update Posted: July 16, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms
Pharmaceutical Solutions
Laxatives
Cathartics
Gastrointestinal Agents